GLP1R and metabolic syndrome: Some clinical and preclinical studies have demonstrated that the contribution to cardiovascular protection of GLP-1 RAs is mainly ascribed to its modest reduction of blood pressure [33], correction of dyslipidemia [34], improvement of microvascular function [35, 36], and anti-oxidization or anti-inflammation [1, 37].